PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Brivaracetam - Epilepsy
PAD Profile : Brivaracetam - Epilepsy Important
Brand Names Include :
Briviact
Important Information :
Reserved for patients who remain uncontrolled or intolerant to all other adjuntive anti-epileptics.
Only for use when levetiracetam has not been effective or tolerated.
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Eslicarbazepine acetate
- Carbamazepine
- Clobazam
- Lacosamide
- Clonazepam
- Perampanel
- Ethosuximide
- Felbamate
- Rufinamide
- Gabapentin
- Stiripentol
- Lamotrigine
- Zonisamide
- Levetiracetam
- Oxcarbazepine
- Phenobarbital
- Piracetam
- Phenytoin
- Pregabalin
- Topiramate
- Sodium valproate
- Sodium valproate
- Cannabidiol
- Vigabatrin
- Cenobamate
- Primidone
- Tiagabine
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
01 February 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Brivaracetam (Briviact®) as an adjunctive therapy in the treatment of partial-onset seizures in epileptic patients from 16 years of age.
Brivaracetam should be reserved for patients with refractory/intractable epilepsy, who remain uncontrolled with, or are intolerant to, all other adjunctive anti-epileptic medicines, carbamazepine, lamotrigine, clobazam, gabapentin, levetiracetam, oxcarbazepine, sodium valproate and topiramate, unless contra-indicated.
Patients should not be initiated on brivaracetam unless levetiracetam has already been shown not to be effective or tolerated.
Brivaracetam will be considered BLUE (with an information sheet) on the traffic light system and a specialist should continue to prescribe for at least 3 months before requesting that a primary care prescriber accepts prescribing responsibility.
Associated BNF Codes
04. Central Nervous System
04.08.01. Control of epilepsy